Potential of dihydropyrimidine dehydrogenase genotypes in personalising 5-fluorouracil therapy among colorectal cancer patients

Potential of dihydropyrimidine dehydrogenase genotypes in personalising 5-fluorouracil therapy among colorectal cancer patients

Background: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the initial and rate-limiting step of the catabolic pathway of toxic metabolites of 5-fluorouracil (5-FU). Several studies have reported that deficiency of DPD and polymorphisms of its gene are related to...

Full description

Bibliographic Details
Main Authors: Ngow, Harris Abdullah, Lay , Kek Teh, Hamzah, Sharina, Hashim, Hazwanie, Bannur, Zakaria, Zakaria, Zainul Amiruddin, Hasbullani, Zakaria, John Kwong, Siew Shia, Henry, Fijeraid, Md Nor, Azmid, Zailani, Mohd, Prabu, Ramasamy, Suneet, S, Salleh, Mohd Zaki
Format: Article
Language:English
Published: International Association of Therapeutic Drug Monitoring and Clinical Toxicology 2011
Subjects:
RC Internal medicine
Online Access:http://irep.iium.edu.my/43026/
http://irep.iium.edu.my/43026/
http://irep.iium.edu.my/43026/1/potential.pdf

Internet

http://irep.iium.edu.my/43026/
http://irep.iium.edu.my/43026/
http://irep.iium.edu.my/43026/1/potential.pdf

Similar Items